Beta Drugs Limited (NSE:BETA)
India · Delayed Price · Currency is INR 1,677.00
-53.00 (-3.06%)
At close: Jul 16, 2025
Beta Drugs Revenue
In the fiscal year ending March 31, 2025, Beta Drugs had annual revenue of 3.62B INR with 22.54% growth. Beta Drugs had revenue of 1.82B in the half year ending March 31, 2025, with 58.69% growth.
Revenue
3.62B
Revenue Growth
+22.54%
P/S Ratio
4.67
Revenue / Employee
9.77M
Employees
371
Market Cap
16.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.62B | 666.42M | 22.54% |
| Mar 31, 2024 | 2.96B | 686.00M | 30.21% |
| Mar 31, 2023 | 2.27B | 432.76M | 23.54% |
| Mar 31, 2022 | 1.84B | 677.16M | 58.31% |
| Mar 31, 2021 | 1.16B | 253.16M | 27.88% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,646.93B |
| HDFC Bank | 2,728.47B |
| Tata Consultancy Services | 2,561.48B |
| Bharti Airtel | 1,729.85B |
| ICICI Bank | 2,006.54B |
| State Bank of India | 3,429.39B |
| Infosys | 1,647.16B |
| Hindustan Unilever | 631.21B |